|
|
|
Volumn 5, Issue 5, 2003, Pages 547-552
|
|
Technology evaluation: LErafAON, NeoPharm
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ANTISENSE OLIGODEOXYNUCLEOTIDE;
CISPLATIN;
CORTICOSTEROID;
DOCETAXEL;
DOXORUBICIN;
EPIRUBICIN;
GEMCITABINE;
HISTAMINE H1 RECEPTOR ANTAGONIST;
HISTAMINE H2 RECEPTOR ANTAGONIST;
LERAFAON;
LIPOSOME;
MITOXANTRONE;
PACLITAXEL;
RAF PROTEIN;
BACKACHE;
CHILL;
CLINICAL TRIAL;
DRUG BLOOD LEVEL;
DRUG DISTRIBUTION;
DRUG FORMULATION;
DRUG MECHANISM;
DRUG SYNTHESIS;
DYSPNEA;
ENCAPSULATION;
EVALUATION;
FEVER;
FLANK PAIN;
FLUSHING;
HUMAN;
HYPERTENSION;
HYPOTENSION;
HYPOXEMIA;
MEDICAL TECHNOLOGY;
NONHUMAN;
REVIEW;
SOLID TUMOR;
THORAX PAIN;
THROMBOCYTOPENIA;
ANIMALS;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS, PHASE I;
HUMANS;
LIPOSOMES;
MICE;
NEOPLASMS;
OLIGODEOXYRIBONUCLEOTIDES;
OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE;
PROTO-ONCOGENE PROTEINS C-RAF;
|
|
EID: 0142154204
PISSN: 14648431
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (7)
|
|
References (0)
|
